- Home
- BEAM vs EVT Comparison
BEAM vs EVT Comparison
Compare BEAM & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- EVT
- Stock Information
- Founded
- BEAM 2017
- EVT 2003
- Country
- BEAM United States
- EVT United States
- Employees
- BEAM N/A
- EVT N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- EVT Finance Companies
- Sector
- BEAM Health Care
- EVT Finance
- Exchange
- BEAM Nasdaq
- EVT Nasdaq
- Market Cap
- BEAM 1.9B
- EVT 1.7B
- IPO Year
- BEAM 2020
- EVT N/A
- Fundamental
- Price
- BEAM $20.75
- EVT $23.97
- Analyst Decision
- BEAM Strong Buy
- EVT
- Analyst Count
- BEAM 11
- EVT 0
- Target Price
- BEAM $48.90
- EVT N/A
- AVG Volume (30 Days)
- BEAM 2.3M
- EVT 115.5K
- Earning Date
- BEAM 08-05-2025
- EVT 01-01-0001
- Dividend Yield
- BEAM N/A
- EVT 8.32%
- EPS Growth
- BEAM N/A
- EVT N/A
- EPS
- BEAM N/A
- EVT 6.63
- Revenue
- BEAM $63,578,000.00
- EVT $69,404,302.00
- Revenue This Year
- BEAM N/A
- EVT N/A
- Revenue Next Year
- BEAM $17.18
- EVT N/A
- P/E Ratio
- BEAM N/A
- EVT $3.55
- Revenue Growth
- BEAM N/A
- EVT N/A
- 52 Week Low
- BEAM $13.53
- EVT $19.20
- 52 Week High
- BEAM $35.25
- EVT $25.83
- Technical
- Relative Strength Index (RSI)
- BEAM 62.58
- EVT 53.91
- Support Level
- BEAM $19.40
- EVT $23.80
- Resistance Level
- BEAM $22.51
- EVT $24.41
- Average True Range (ATR)
- BEAM 1.32
- EVT 0.23
- MACD
- BEAM 0.13
- EVT -0.06
- Stochastic Oscillator
- BEAM 79.98
- EVT 31.06
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.